HOME >> BIOLOGY >> NEWS
24-Wk data from CONTEXT trial comparing GW433908/ritonavir QD & BID to Lopinavir/ritonavir BID

regimen over a period of 48 weeks. Results from the SOLO trial were presented in November 2002 at the 6th International Congress on Drug Therapy in HIV Infection in Glasgow, United Kingdom.

NEAT was a phase III, randomized, open-label, parallel-group 48-week study that compared 908 BID and nelfinavir BID, both in combination with ABC and 3TC in 249 antiretroviral therapy-nave patients. The primary endpoint of the NEAT study was the proportion of subjects with vRNA <400 c/mL at 24 and 48 weeks. Interim 24-week data from NEAT were presented in September at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICACC) in San Diego, and 48-week data are being presented here today.

Once approved, GSK will market 908 and GSK and Vertex will co-promote it in the United States and key markets in Europe.

GlaxoSmithKline is one of the world's leading research-based pharmaceutical and healthcare companies and an industry leader in HIV research and therapies. The company is engaged in basic research programs designed to investigate new targets to treat HIV.

This press release may contain forward-looking statements, including that 48-week interim analysis of the NEAT and SOLO studies in GlaxoSmithKline's pivotal program for 908 is indicative of a promising clinical and commercial outlook for 908, once approved. While management makes its best efforts to be accurate in making forward-looking statements, such statements are subject to risks and uncertainties that could cause Vertex's actual results to vary materially. These risks and uncertainties include, among other things, the risk that approval will be delayed or will not be obtained, that 908 will not be commercially successful, and those other risks listed under Risk Factors in Vertex's form 10-K filed with the Securities and Exchange Commission on April 1, 2002.


'"/>

Contact: Amy Kling
akling@pcipr.com
312-558-1770
Public Communications Inc.
14-Feb-2003


Page: 1 2 3 4

Related biology news :

1. Phase II trials of second-generation antisense cancer drug planned following successful early study
2. Innovative ceramic-on-metal hip replacements to undergo clinical trials
3. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
4. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
5. Pharmacogenomics could replace trial-and-error with science from the human genome
6. Wilex & Fox Chase Cancer Center begin trial w/ novel compound targeting tumor invasion & metastasis
7. Small trial shows daclizumab add-on therapy improves MS outcome
8. Tigecycline - antibiotic evaluated in surveillance trial
9. OneWorld Health completes enrollment, treatment in Phase III India trial
10. Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins
11. First large-scale trial of genetically personalised treatment for breast cancer to start soon

Post Your Comments:
(Date:8/1/2014)... of a new study, including two Simon Fraser ... industry representatives and policymakers must collaborate closely on ... gas development. Viorel Popescu and Maureen Ryan, David ... Sciences department, are among eight international co-authors of ... Ecology and the Environment . , Shale gas ...
(Date:7/31/2014)... AMHERST, Mass. A first-of-its-kind study of bigeye tuna ... Lutcavage, director of the Large Pelagics Research Center at ... that these fish cover a wide geographical range with ... shelf, and they favor a high-use area off Cape ... research, which used a new approach to study one ...
(Date:7/31/2014)... Latinos are the largest minority group in the United ... of Latinos are obese and are 1.2 times as ... , NYU College of Nursing student researcher Lauren Gerchow, ... factors that contribute to this problem by compiling a ... patterns in Latina women recently published in Nursing ...
Breaking Biology News(10 mins):Scientists warn time to stop drilling in the dark 2Scientists warn time to stop drilling in the dark 3Study of bigeye tuna in Northwest Atlantic uses new tracking methods 2Study of bigeye tuna in Northwest Atlantic uses new tracking methods 3NYU research looks to combat US Latina immigrant obesity 2
(Date:8/1/2014)... , Aug. 1, 2014 Research ... "The World Market for Flow Cytometry in ... http://photos.prnewswire.com/prnh/20130307/600769 ... are now an important component of advanced IVD ... instruments for cancer diagnostics, but their newer clinical ...
(Date:8/1/2014)... , Aug. 1. 2014 As one ... the 2014 AACC Annual Meeting & Clinical Lab Expo ... and patient care are introduced to the healthcare world. ... the Expo,s 650 exhibitors will include the latest diagnostic ... Advances in smartphones and biosensors have enabled the ...
(Date:8/1/2014)... , Aug. 1, 2014 One of the ... of personalized medicine, which is the practice of using ... to a patient,s individual biology. Personalized diagnostics—laboratory analyses that ... role in the lab,s future. This fall, AACC ... the latest science in this exciting field and the ...
(Date:8/1/2014)... , August 1, 2014 According ... Research "Biophotonics Market - Global Industry Analysis, Size, Share, ... was valued at USD 25.16 billion in 2013, which ... growing at a CAGR of 10.4% from 2014 to ... at  http://www.transparencymarketresearch.com/biophotonics-market.html Increasing demand for accurate ...
Breaking Biology Technology:The World Market for Flow Cytometry in IVD Applications 2Lab-on-a-Chip Technology to Be Featured at 2014 AACC Annual Meeting & Clinical Lab Expo 2Lab-on-a-Chip Technology to Be Featured at 2014 AACC Annual Meeting & Clinical Lab Expo 3First-Ever AACC Virtual Conference to Focus on Personalized Diagnostics 2Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 2Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 3Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 4
Cached News: